Last reviewed · How we verify
Jincaopian Tablets
Jincaopian Tablets is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to treat respiratory and immune-related conditions.
Jincaopian Tablets is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to treat respiratory and immune-related conditions. Used for Respiratory conditions and immune support (specific indication under Phase 3 evaluation).
At a glance
| Generic name | Jincaopian Tablets |
|---|---|
| Also known as | ZY5301 |
| Sponsor | Beijing Konruns Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
The tablet formulation combines herbal components traditionally used in Chinese medicine to support respiratory health and immune function. While the exact molecular targets are not well-characterized in Western pharmacological literature, the preparation is believed to work through multiple pathways including anti-inflammatory and immunomodulatory effects. The specific active constituents and their mechanisms require further clinical characterization.
Approved indications
- Respiratory conditions and immune support (specific indication under Phase 3 evaluation)
Common side effects
Key clinical trials
- A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease (PHASE3)
- The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jincaopian Tablets CI brief — competitive landscape report
- Jincaopian Tablets updates RSS · CI watch RSS
- Beijing Konruns Pharmaceutical Co., Ltd. portfolio CI